Lifevantage (NASDAQ:LFVN) Stock, Quote.Headers.trade-ideas

Lifevantage

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

LFVN

MDRR

MPAA

TLYS

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.

Insiders Buying LifeVantage, Motorcar Parts of America And 2 Other Stocks

Earnings

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

AEHL

AXLA

JOAN

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 250 points on Tuesday.

The Dow traded up 0.74% to 34,814.53 while the NASDAQ rose 1.73% to 13,942.34. The S&amp;P 500, also rose, gaining, 1.34% to 4,492.62.

Dow Surges 250 Points; Smucker Earnings Top Estimates

Small Cap

Movers

AGIL

AIXI

BGLC

BNOX

CACO

EBET

FLAG

GSAT

GSHD

HKIT

ICCT

INBX

IONR

LXEH

NBSE

NCNC

NFTG

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PLSE

RETO

SECO

SISI

TIGR

TIVC

TSHA

TTOO

VRRM

Gainers


	Axcella Health Inc.  (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.


Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Lifevantage Corp

WIIM

LifeVantage shares are trading higher after the company announced in vitro study results showing synergistic effects of new two-product system on GLP-1 production

Study Highlights Significant Increase In GLP-1 Synthesis And Downregulation Of DPP-4 Gene Expression, Enhancing GLP-1 Availability For Weight Management And Glucose Regulation
The study, which began in May and concluded at the end of June 2024, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation.
Key genes involved in the production and regulation of GLP-1 were thoroughly examined, including:
<ul>
<li>GCG: Directs the production of Proglucagon, a precursor protein essential for GLP-1 synthesis.</li>
<li>PCSK1: Encodes for enzymes that cleave Proglucagon into active GLP-1.</li>
<li>GLP1R: Facilitates the creation of receptors that GLP-1 binds to, enabling its biological activity.</li>
<li>DPP-4: An enzyme that degrades GLP-1, reducing the amount available in the body.</li>
</ul>
The study used ELISA (Enzyme-Linked Immunosorbent Assay) to quantify total GLP-1 production, complemented by fluorescent microscopy to visualize the outcomes. The research focused on determining the synergistic potential of the active blends from the two-product system, which was designed to enhance the body's GLP-1 production through a dual mechanism: direct activation of L-cells with a proprietary blend of eight naturally-derived ingredients and optimization of the gut microbiome environment using resistant starches and fibers.&#x2A;
Results from the in vitro study revealed not only a significant increase in GLP-1 production but also a synergistic activation of the key genes responsible for its synthesis and regulation. Notably, there was a downregulation of DPP-4 gene expression, which allows for more GLP-1 to be available to work within the body.&#x2A;

Biotech

General

LifeVantage Announces In Vitro Study Results Showing Synergistic Effects Of New Two-Product System On GLP-1 Production

Guidance

LifeVantage Sees FY24 Revenue $200M-$210M, Adj. EPS $0.70-$0.80

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.21 by 33.33 percent. The company reported quarterly sales of $48.931 million which missed the analyst consensus estimate of $50.952 million by 3.97 percent. This is a 9.76 percent decrease over sales of $54.221 million the same period last year.

Earnings Misses

Lifevantage Q4 2024 Adj. EPS $0.14 Misses $0.21 Estimate, Sales $48.931M Miss $50.952M Estimate

Rumors

Watching Lifevantage; Traders Circulate Unconfirmed Research Firm Comments Suggesting The The Co Has Disclosed That Its Upcoming Weight Loss Product Launch In October Is Actually A GLP-1 Treatment, Was Said In A Recent CEO Interview, Where He Called The New GLP-1 Drug "Game Changing"

Lifevantage Sees FY24 Revenue $202M-$205M

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.16 by 31.25 percent. This is a 162.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $48.245 million which missed the analyst consensus estimate of $52.182 million by 7.54 percent. This is a 10.23 percent decrease over sales of $53.741 million the same period last year.

Earnings Beats

Lifevantage Q3 2024 Adj EPS $0.21 Beats $0.16 Estimate, Sales $48.245M Miss $52.182M Estimate

LifeVantage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health at the cellular level, is proud to announce the launch of its TrueScience&#xAE; Activated Skin Care Collection, marking a significant advancement in skincare technology and formulation. Building on the successful October 2023 launch of <a href="https://www.globenewswire.com/Tracker?data=tvmv4aRbP5dZ-3-KbHQhMjhfZvy734vvBS1ci_vUMOLYBN2OiWoDcwk24KYhl9r7YHYeymlDI-7hYWhPNTaFR3OC0uvx21tzEExA-scpBorT4uhseyc-rKcQjbwtvXw5AG0yw1e-RRO7YSvf3AZiU1xnbmH4MSCCX2VY5Ssb8UbL_wbEScNc6BApffEuthxh75OfILpB2O5uZrn5R5ir2rVuOTb08iGzhxNoV1ep2pwKSDgBBqNHzhDPNQJWgHVAdX_l8Ufo9AQ8z8MY5XXvTWcWlxXtsFP5S3bXE7ikXQt24KAJbMT119hcj0-BBUPRSfiDhuKxXTf150zDhFpyE7Vc5sxz5GFamleLzYQ5rZKLZYQh1v_1IVp1rDnMAZXW9jLHGYeE2AVtIQprJwYJErLDz9hZ2fYkERjQyl0n-G3aBCA48G7FHCYiqs7GOL9LxzN4jy6lWQHe8d8ZL_1rjhV40KnJlZ6W61TO6KajfB1ZhzGolg5R1k3OIpWCZa67">TrueRenew</a> Daily Firming Complex, a better-than-retinol alternative, LifeVantage's entire skincare offering has been enhanced to provide skin health activation in every step. The Collection delivers a simple regimen of multi-tasking products that meet the sophisticated needs of today's busy consumers.&nbsp;
The products were first revealed March 2 in Canada and Europe where they were immediately available to Consultants and Customers. The global launch continues throughout the month and into April, as they launch at various market events across the globe.
The reimagined TrueScience lineup features TrueRenew plus three, refreshed, reimagined, clean product formulas: TrueClean Refining Cleanser, TrueLift Illuminating Eye Cream, and TrueHydrate Brightening Moisturizer. Each is designed with cutting-edge science, including a patented Nrf2 ingredient blend plus additional premium, planet-friendly ingredients proven to support skin health and deliver visible anti-aging results, including brighter skin in as little as seven days.
Steve Fife, President and CEO of LifeVantage, expressed his excitement about the new collection: "TrueRenew was just the beginning of a new era of activated skincare for LifeVantage. With the TrueScience Activated Skin Care Collection, we've kept the ingredients our customers love and elevated everything else to exceed their expectations. The Collection offers advanced solutions for the smart skincare enthusiast, underscoring our commitment to ensuring LifeVantage Consultants have the very best, results-driven products to share and grow their businesses. This launch also reaffirms our position as a leader in innovative skincare, delivering on the promise of activating skin health to reveal every customer's natural radiance."
TrueClean Refining Cleanser: A naturally radiant complexion begins with TrueClean Refining Cleanser. This product goes beyond basic cleansing with gentle exfoliation powered by pomegranate enzymes that effectively remove impurities and dead skin without stripping the skin's natural oils. Enhanced with ginger root and bisabolol for added comfort, the cleanser now offers eight additional benefits, supported by five new ingredient studies, establishing a higher standard for clean, refreshed skin.
TrueLift Illuminating Eye Cream: Targeting the delicate eye area, TrueLift Illuminating Eye Cream offers 360° age correction. This powerful formula visibly improves seven visible signs of aging, including dark circles, under-eye bags, fine lines, crow's feet, eyelid roughness, and puffiness, while also visibly lifting the eyelid fold and crease. With two additional benefits and 12 new ingredient studies, this eye cream provides an instant cooling effect and contains caffeine for an alert, revitalized appearance.
TrueHydrate Brightening Moisturizer: Discover luminous, youthful skin in as little as seven days with TrueHydrate Brightening Moisturizer, an anti-aging powerhouse. This potent formulation rapidly delivers moisture to the skin, boosts its glow, and brightens the overall complexion. It targets age spots for visible reduction and fights against the development of new dark spots, providing a full spectrum of anti-aging advantages.
Valued at $146.7 billion in 2021, the skincare industry is expected to grow to $273.3 billion by 2031.1 Modern consumers seek products that deliver proven results, pack multiple benefits, and come from environmentally conscious companies. LifeVantage's TrueScience Activated Skin Care Collection directly answers these demands, featuring scientifically-backed ingredients that tackle various skin issues, all while upholding the Company's commitment to its clean standards.
For more information on the Activated Skin Care Collection and to experience the future of skincare, visit the LifeVantage website (<a href="https://www.globenewswire.com/Tracker?data=EzjZjB4HZcJFUQckfw38HxTzSb_idlMxlPbzHnL3Q8sjawnRyT0b5A6NrGHdW8Clsr9rUjxL6WKf3RghBVjMhKA869faujlH6mdjNp8ZA_7QC51mYOTTtH9xD2UQmaiHwkQDCb_RJm4S2X2rTbBNMgaONigs3bxgabRw04QEDibuGg0isxnpqItSvjTCWQRLRbjmvSam5b122iM3F9lYEYLn6hXGDBfAGNiPslR-pkc3CBc6l910uz2ShpRKdHiLfu85lMmPsbZEvQHCS1MF-bfj4zFzFFir7CfCkMfJcf_Dj89mjkvrCCs2eR3YFFqDHx5sPw3MXJN9SCV28KFnUhrPFhiaMWnYiDWt1MJkk0XOOZq485EVm5UHYxzL7TNw-lMa3NLjzPLv-n0iS_-62uH6ae9YeYhq3-DeqHAise7wcUoeZPy4SPNKhBZvCZy5tuB_4dH3DY0SkBadyCMeoLb4NSiK-m-DTjGxP9UcVOByXam9jC-2s0oxgn2UdxFY3TwWjbXOGolw5ieI42unzY6zuvNUCzrtaW6-42SMPl-zSsBNk1g7mdj0DEnUZ8w_L3JYIkvjV3-p8hrOI9m9GhuIbDo-mtUkDufDyYVKfz3W9cMgav_EUQJI70scqU7Z">www.lifevantage.com</a>).&nbsp;

LifeVantage Introduces The TrueScience Activated Skin Care Collection

LifeVantage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, proudly announces the successful expansion of LV360 into Canada, Mexico, and its European markets including the UK, Ireland, Germany, Austria, Belgium, Spain, and the Netherlands. &nbsp;
The Company's Evolve Compensation Plan and Rewards Circle customer loyalty program went into effect February 1 in these markets after a successful launch in the U.S., Australia, New Zealand, and Japan, in March of last year.
"LV360 is the answer to the evolving direct sales industry. We strategically decided to not shy away from the need to change and committed over two years ago to modernizing our model and providing our Consultants with the tools and incentives they need to succeed in today's world," said Steve Fife, President and CEO of LifeVantage. "We are thrilled that this innovation is reaching even more members of our Activation Nation after demonstrating successes for those who moved to Evolve last year."
The Evolve Compensation Plan rewards Independent Consultants generously, offering diverse income streams and opportunities to accelerate their path to success. The approach caters to the dynamic needs of modern entrepreneurs and affiliates who are driven to share and sell products to their networks as well as those who also want to build robust, collaborative teams. Early income bonuses foster effective business strategies from the start and performance and mentorship bonuses acknowledge and reward outstanding achievements as Consultants continue along their success path.
In a highly competitive direct selling market, LifeVantage is keenly aware of the need to stay at the forefront. With LV360 and its forward-thinking approach, LifeVantage is well-positioned to capitalize consumer and gig trends, while attracting an expanding Customer base.
"Anyone looking for supplemental income and multiple paths to success should look no further than LifeVantage," said Fife. "We will continue to lead the way in innovation with the very best products and best-in-class Consultant and Customer experiences."

LifeVantage Announces Expansion Of LV360 Into Canada, Mexico, And European Markets

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.04 by 150 percent. This is a 242.86 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $51.62 million which missed the analyst consensus estimate of $54.65 million by 5.54 percent. This is a 3.80 percent decrease over sales of $53.66 million the same period last year.

Lifevantage Q2 Adj EPS $0.10 Beats $0.04 Estimate, Sales $51.62M Miss $54.65M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) is estimated to report quarterly earnings at $0.73 per share on revenue of $208.06 million.
&bull; Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) is expected to report quarterly earnings at $3.57 per share on revenue of $1.32 billion.
&bull; ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $4.56 billion.
&bull; Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $3.25 billion.
&bull; Cambridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATC#NASDAQ">CATC</a>) is estimated to report quarterly earnings at $0.93 per share on revenue of $38.38 million.
&bull; Malibu Boats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBUU#NASDAQ">MBUU</a>) is likely to report quarterly earnings at $0.48 per share on revenue of $219.70 million.
&bull; Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) is expected to report quarterly earnings at $2.24 per share on revenue of $2.46 billion.
&bull; Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $6.12 billion.
&bull; Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $976.03 million.
&bull; MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) is projected to report quarterly earnings at $0.94 per share on revenue of $2.85 billion.
&bull; MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) is estimated to report quarterly earnings at $3.29 per share on revenue of $662.73 million.
&bull; Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is likely to report quarterly loss at $0.22 per share on revenue of $14.21 billion.
&bull; Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) is likely to report quarterly earnings at $2.21 per share on revenue of $34.66 billion.
&bull; JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) is likely to report quarterly loss at $0.28 per share on revenue of $2.28 billion.
&bull; PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) is projected to report quarterly earnings at $3.22 per share on revenue of $4.48 billion.
&bull; M.D.C. Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDC#NYSE">MDC</a>) is expected to report quarterly earnings at $1.49 per share on revenue of $1.29 billion.
&bull; Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) is expected to report quarterly earnings at $2.58 per share on revenue of $2.23 billion.
&bull; Chunghwa Telecom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHT#NYSE">CHT</a>) is estimated to report earnings for its fourth quarter.
&bull; Hope Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $138.35 million.
&bull; Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) is estimated to report quarterly earnings at $0.79 per share on revenue of $42.22 million.
&bull; HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) is projected to report quarterly earnings at $5.04 per share on revenue of $16.51 billion.
&bull; A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) is expected to report quarterly earnings at $0.95 per share on revenue of $983.30 million.
&bull; General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $38.75 billion.
&bull; Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is expected to report quarterly earnings at $1.88 per share on revenue of $6.07 billion.
&bull; United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) is likely to report quarterly earnings at $2.47 per share on revenue of $25.48 billion.
&bull; Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) is likely to report quarterly earnings at $0.88 per share on revenue of $19.34 billion.
&bull; BBVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBVA#NYSE">BBVA</a>) is likely to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) is expected to report quarterly earnings at $1.72 per share on revenue of $36.98 million.
&bull; Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $1.47 billion.
&bull; Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $477.78 million.
&bull; Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is likely to report quarterly earnings at $0.71 per share on revenue of $674.77 million.
&bull; Artisan Partners Asset (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APAM#NYSE">APAM</a>) is estimated to report quarterly earnings at $0.74 per share on revenue of $249.60 million.
&bull; Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) is expected to report quarterly earnings at $1.66 per share on revenue of $586.33 million.
&bull; Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $6.12 billion.
&bull; Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) is estimated to report quarterly earnings at $5.12 per share on revenue of $9.93 billion.
&bull; Juniper Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) is projected to report quarterly earnings at $0.64 per share on revenue of $1.41 billion.
&bull; RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) is expected to report quarterly earnings at $8.10 per share on revenue of $1.89 billion.
&bull; First Interstate BancSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIBK#NASDAQ">FIBK</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $252.73 million.
&bull; Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) is likely to report quarterly earnings at $0.93 per share on revenue of $1.18 billion.
&bull; Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $54.65 million.
&bull; Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $9.29 billion.
&bull; Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is likely to report quarterly earnings at $0.94 per share on revenue of $9.63 billion.
&bull; Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is likely to report quarterly earnings at $3.27 per share on revenue of $5.60 billion.
&bull; Hawaiian Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HA#NASDAQ">HA</a>) is likely to report quarterly loss at $2.34 per share on revenue of $668.97 million.
&bull; Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) is estimated to report quarterly earnings at $1.95 per share on revenue of $1.20 billion.
&bull; Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) is expected to report quarterly earnings at $1.59 per share on revenue of $85.22 billion.
&bull; Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) is projected to report quarterly earnings at $1.59 per share on revenue of $85.26 billion.
&bull; Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) is expected to report quarterly earnings at $2.12 per share on revenue of $545.81 million.
&bull; UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) is estimated to report quarterly earnings at $1.76 per share on revenue of $360.69 million.
&bull; Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $861.46 million.
&bull; Boston Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) is projected to report earnings for its fourth quarter.
&bull; Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) is projected to report quarterly earnings at $1.86 per share on revenue of $3.14 billion.
&bull; Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) is likely to report quarterly earnings at $1.13 per share on revenue of $3.68 billion.
&bull; Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) is likely to report quarterly earnings at $0.80 per share on revenue of $223.97 million.
&bull; Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) is expected to report quarterly earnings at $1.38 per share on revenue of $247.50 million.
&bull; Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) is likely to report quarterly earnings at $2.94 per share on revenue of $2.40 billion.
&bull; Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) is expected to report quarterly earnings at $0.59 per share on revenue of $594.92 million.
&bull; First Commonwealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCF#NYSE">FCF</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $123.59 million.
&bull; Powell Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $182.04 million.
&bull; Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is expected to report quarterly earnings at $2.78 per share on revenue of $61.13 billion.
&bull; Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) is projected to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

APAM

BBVA

CATC

CVLT

ENVA

FBIN

FIBK

GOOG

GOOGL

HOPE

HUBB

JBLU

JNPR

LFUS

MANH

MBUU

MDLZ

MPLX

MSCI

MSFT

MTCH

POWL

SBUX

SWKS

UMBF

Earnings Scheduled For January 30, 2024

Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-01-30. Here's what investors need to know before the announcement.
Analysts estimate that Lifevantage will report an earnings per share (EPS) of $0.04. 
Lifevantage bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Here's a look at Lifevantage's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.13</td>
<td>0.17</td>
<td>0.08</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-21.73%</td>
<td>23.88%</td>
<td>22.37%</td>
<td>0.76%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Lifevantage were trading at $5.78 as of January 26. Over the last 52-week period, shares are up 47.75%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LFVN/earnings">To track all earnings releases for Lifevantage visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Lifevantage

LifeVantage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes, today announced that Company scientists have completed a study on the impact Protandim&#xAE; Nrf2 Synergizer&#xAE; and TrueScience&#xAE; Liquid Collagen have on cellular health. The study results showed that when combined, the products work together to help cells accurately respond to stress levels and recover more quickly, supporting the body's immune function. &nbsp;
"When cells are stressed they send out signals asking for help from the immune system," explained Lisa Barnes, Vice President of Research &amp; Development. "However, even after the stressor is eliminated, it can be common for this signaling to continue, causing the immune system to waste precious energy trying to fix a problem that no longer exists. This unchecked cycle can lead to significant health concerns. The synergistic benefits of Protandim&#xAE; Nrf2 Synergizer&#xAE; and TrueScience&#xAE; Liquid Collagen, help break this repetitive stress cycle by reducing unnecessary signaling, allowing cells to get back to their optimal function, which in this case is producing collagen."
Barnes continued, "The study shows why people are seeing such incredible results with these two products. Together, they create a potent combination that drives cellular rebalance, helping to ensure cells are functioning properly. It's like sending your cells to a day at the spa, like the effect people are trying to achieve with ice plunges or cryotherapy. It's amazing how these two products work with your body to support its natural functions."
"The results of this study are further proof that LifeVantage's unique emphasis on activation provides the optimal approach to health and wellness," said Steve Fife, President, and Chief Executive Officer. "Our products are clearly differentiated and have demonstrated their effectiveness in amplifying the body's natural processes to improve health starting at the cellular level. The science behind our products is one of the pillars of LifeVantage's competitive strength and supports the compelling business opportunity we offer for entrepreneurial minded individuals."
Scientific Investigation Spurred by the Consumer Experience The study was designed after consumers provided significant anecdotal evidence about unexpected, positive results in gut health, joint health, along with improvements in overall energy and clarity. To understand why, Barnes and team devised a study in three parts: a dose-finding study, a gene expression study to verify dose timing and concentration, and a global gene expression study using RNA sequencing.
Specifically, the study looked at the products' influence on fibroblasts. Found throughout the body, fibroblasts produce and organize components of the skin that act as the scaffold or support for the skin through proteins, including collagen, elastin, and laminin. Fibroblasts not only produce collagen and other proteins that make up the extracellular matrix for the skin, but they also perform the same function for other organs, such as the intestines, spleen, brain, lung, liver, kidney, and blood vessels.
The gene expression study showed 13,195 genes distributed over 18,671 cellular pathways were influenced in the fibroblasts. Around 21% (2,786 genes) were significantly up, or downregulated either by Protandim Nrf2 Synergizer&#xAE;, TrueScience&#xAE; Liquid Collagen, or a combination of the two. Of the 2,786 genes measured, the combination of the two products synergistically influenced 2,439 genes (p&lt;0.05), of which 418 genes (17%) were significantly up- (195 genes) or downregulated (223 genes).
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

LifeVantage Study Reveals Synergistic Effects Of Protandim Nrf2 Synergizer And TrueScience Liquid Collagen

Management

LifeVantage Appoints Raymond Greer As Chairman Of Board, Succeeding Garry Mauro Who Will Continue To Serve As Member Of Board

Darwin Lewis, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), reported a large insider buy on November 21, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914623000223//Archives/edgar/data/849146/000084914623000223/0000849146-23-000223-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Lewis purchased 17,185 shares of Lifevantage. The total transaction amounted to $105,000. 
Lifevantage shares are trading down 1.2% at $5.78 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lifevantage Board Member Makes $105K Stock Purchase

Cynthia Latham, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), reported a large insider buy on November 21, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914623000222//Archives/edgar/data/849146/000084914623000222/0000849146-23-000222-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Latham purchased 17,185 shares of Lifevantage. The total transaction amounted to $105,000. 
Lifevantage shares are trading down 1.2% at $5.78 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member of Lifevantage Purchased $105K In Stock

Michael Beindorff, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), reported a large insider buy on November 21, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914623000218//Archives/edgar/data/849146/000084914623000218/0000849146-23-000218-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Beindorff purchased 17,185 shares of Lifevantage. The total transaction amounted to $105,000. 
Lifevantage shares are trading down 1.2% at $5.78 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member At This Consumer Staples Company Buys $105K of Stock

Erin Brockovich, Director at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), reported a large insider buy on November 21, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914623000219//Archives/edgar/data/849146/000084914623000219/0000849146-23-000219-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Brockovich purchased 17,185 shares of Lifevantage. The total transaction amounted to $105,000. 
Lifevantage shares are trading down 1.2% at $5.78 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director of Lifevantage Purchased $105K In Stock

Raymond B Greer, Board Member at Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), reported a large insider buy on November 21, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000849146/000084914623000221//Archives/edgar/data/849146/000084914623000221/0000849146-23-000221-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Greer purchased 17,185 shares of Lifevantage. The total transaction amounted to $105,000. 
Lifevantage shares are trading down 1.2% at $5.78 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000849146">Check Out The Full List Of Lifevantage's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member of Lifevantage Makes $105K Buy

<h3>Gainers</h3>
<ul>
<li>Bruush Oral Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRSH#NASDAQ">BRSH</a>) stock increased by 25.6% to $0.2 during Friday's regular session. As of 12:31 EST, Bruush Oral Care's stock is trading at a volume of 1.1 million, which is 77.0% of its average full-day volume over the last 100 days. </li>
<li>Natural Grocers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NYSE">NGVC</a>) shares increased by 20.62% to $15.44. As of 12:31 EST, this security is trading at a volume of 117.0K shares, making up 375.5% of its average full-day volume over the last 100 days. The company's market cap stands at $351.0 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) stock moved upwards by 17.41% to $2.09. Trading volume for Beauty Health's stock is 6.3 million as of 12:31 EST. This is 148.6% of its average full-day volume over the last 100 days. The company's market cap stands at $274.3 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Stryve Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAX#NASDAQ">SNAX</a>) shares rose 16.47% to $3.04. The company's market cap stands at $5.6 million. The company's, Q3 earnings came out 3 days ago. </li>
<li>Lifevantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>) stock increased by 15.54% to $5.65. Trading volume for Lifevantage's stock is 86.6K as of 12:31 EST. This is 85.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $71.8 million. </li>
<li>Edible Garden AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) stock rose 12.99% to $0.46. Trading volume for Edible Garden AG's stock is 358.2K as of 12:31 EST. This is 24.7% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Davis Commodities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) shares declined by 14.5% to $1.03 during Friday's regular session. As of 12:31 EST, this security is trading at a volume of 580.2K shares, making up 54.3% of its average full-day volume over the last 100 days. The company's market cap stands at $25.1 million. </li>
<li>Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) stock declined by 10.32% to $68.97. As of 12:31 EST, Spectrum Brands Holdings's stock is trading at a volume of 989.7K, which is 181.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.4 billion. As per the news, the Q4 earnings report came out today. </li>
<li>22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) stock decreased by 9.71% to $0.28. Trading volume for 22nd Century Group's stock is 639.7K as of 12:31 EST. This is 96.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.6 million. </li>
<li>Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) shares declined by 9.3% to $11.22. The company's market cap stands at $615.4 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Paranovus Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVS#NASDAQ">PAVS</a>) shares decreased by 9.16% to $2.48. The current volume of 63.4K shares is 192.6% of Paranovus Enter's average full-day volume over the last 100 days (last updated at 12:31 EST). The company's market cap stands at $18.1 million. </li>
<li>Benson Hill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NYSE">BHIL</a>) stock declined by 9.16% to $0.21. As of 12:31 EST, this security is trading at a volume of 770.3K shares, making up 52.7% of its average full-day volume over the last 100 days. The company's market cap stands at $43.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BHIL

BRSH

DTCK

EDBL

ISPR

NGVC

PAVS

SKIN

SNAX

XXII

12 Consumer Staples Stocks Moving In Friday's Intraday Session

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Lifevantage (NASDAQ:<a href="https://investorplace.com/stock-quotes/lfvn-stock-quote/">LFVN</a>) just reported results for the third quarter of 2024.<ul><li>Lifevantage reported earnings per share of 21 cents. This was above the analyst estimate for EPS of 16 cents.</li><li>The company reported revenue of $48.25 million.</li><li>This was 7.54% worse than the analyst estimate for revenue of $52.18 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/lfvn-stock-earnings-lifevantage-for-q3-of-2024/">LFVN Stock Earnings: Lifevantage Beats EPS, Misses Revenue for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LFVN Stock Earnings: Lifevantage Beats EPS, Misses Revenue for Q3 2024

LifeVantage Corporation (LFVN) Q3 2024 Earnings Call Transcript

As the economy rebounds from tight monetary policies, small caps are poised to benefit from the cyclical upturn due to their greater sensitivity to economic conditions than large caps. Thus, it could be wise to invest in these three undervalued small-cap stocks: LifeVantage Corp. (LFVN), Hudson Global (HSON), and SigmaTron International (SGMA) before they take off. Read more... Investing in small-cap companies can be both exhilarating and daunting. These smaller companies, typically with market capitalizations between $300 million and $2 billion, have the potential to soar or stumble, making them high-risk, high-reward investments. For those with a keen eye and a bit of courage, the payoff can be significant if the company experiences massive growth.
In this context, I have highlighted three fundamentally sound small-cap stocks, LifeVantage Corporation (<a href="https://stocknews.com/stock/LFVN/">LFVN</a>), Hudson Global, Inc. (<a href="https://stocknews.com/stock/HSON/">HSON</a>), and SigmaTron International, Inc. (<a href="https://stocknews.com/stock/SGMA/">SGMA</a>). These companies are currently trading at a discount to their peers, making them attractive picks for investors looking to capitalize on undervalued opportunities.
The global economy is on an upswing, with the World Bank recently upgrading its growth forecast to <a href="https://www.marketwatch.com/story/u-s-growth-is-exceptional-world-bank-sees-america-fueling-the-global-economy-in-2024-0227945c">2.6% for this year</a>, buoyed by robust performance in the United States. The bank's latest outlook marks an increase from the 2.4% growth for 2024 predicted in January. This positive economic backdrop makes now an excellent time to consider small-cap stocks.
<a href="https://www.investopedia.com/terms/s/small-cap.asp">Small-cap stocks</a>, with market capitalizations between $300 million and $2 billion, often present growth prospects that larger companies cannot match. As the economy recovers from a Fed-induced slowdown, small-cap companies are well-positioned to benefit from increased consumer spending and business activity.
Historically, lower interest rates and accommodative monetary policies have bolstered small-cap stocks, and with potential rate cuts on the horizon, the investment landscape looks promising. Over the past 35 years, <a href="https://www.visualcapitalist.com/sp/beyond-big-names-the-case-for-small-and-mid-cap-stocks/#:~:text=Over%20the%20last%2035%20years,%2B3%2C176%25%20for%20mid%20caps.">small- and mid-cap stocks have consistently outperformed</a> their larger counterparts.
According to Yahoo Finance, from February 1989 to February 2024, large-cap stocks returned 1,664%, while small-caps and mid-caps boasted returns of 2,062% and 3,176%, respectively. This historical outperformance underscores the potential of small-cap investments, particularly in the current economic climate.
Given these favorable trends, let's take a look at the fundamentals of the stocks mentioned above.
LifeVantage Corporation (<a href="https://stocknews.com/stock/LFVN/">LFVN</a>)
LFVN engages in identifying, researching, developing, formulating, selling, and distributing nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. It has a market cap of $80.20 million.
On March 15, the company paid its shareholders a quarterly dividend of $0.04 per share. The company pays an annual dividend of $0.16, which translates to a 2.54% yield higher than the four-year average yield of 2.38%.
In February, LFVN expanded its LV360 initiative into Canada, Mexico, and several European markets, including the United Kingdom, Ireland, Germany, Austria, Belgium, Spain, and the Netherlands. The Evolve Compensation Plan and Rewards Circle program, effective February 1, offers Independent Consultants diverse income streams and team-building opportunities.
This expansion follows a successful launch in the United States, Australia, New Zealand, and Japan last March. LFVN aims to stay competitive in the direct selling market by leveraging consumer and gig trends to attract a growing customer base.
In terms of forward non-GAAP P/E, LFVN is trading at 9.68x, 43% lower than the industry average of 16.98x. Likewise, the stock's forward EV/Sales and Price/Sales multiples of 0.38 and 0.40 are 77.9% and 67.2% lower than their respective industry averages of 1.70 and 1.21.
LFVN's trailing-12-month gross profit margin of 79.32% is 124.8% higher than the 35.29% industry average. Likewise, its trailing-12-month levered FCF margin and ROTA of 6.93% and 5.87% are 21.7% and 24.9% higher than the respective industry averages of 5.70% and 4.70%.
In the second quarter, which ended December 31, 2023, LFVN reported revenue and gross profit of $51.62 million and $40.56 million, respectively. The company's non-GAAP net income and adjusted EPS amounted to $ 1.37 million and $0.10 compared to the prior year's losses of $823 thousand and $0.07 per share, respectively. Also, its adjusted EBITDA improved by 289% from the year-ago value to $3.09 million.
For the fiscal first quarter ending September 2024, LFVN's revenue is expected to amount to $49.63 million, while its EPS is forecasted to settle at $0.16. Further, its EPS and revenue are expected to rise 7.7% and 1.8% year-over-year to $0.70 and $205.84 million, respectively, in the fiscal year ending June 2025. Moreover, it topped the consensus EPS estimates in three of the trailing four quarters.
The stock has gained 52.8% over the past year to close the last trading session at $6.29.
LFVN's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted optimally.
It has an A grade for Value, Sentiment, and Quality. It is ranked #2 out of 10 stocks in the A-rated <a href="https://stocknews.com/category/medical-consumer-goods/">Medical – Consumer Goods</a> industry. To see additional LFVN ratings for Growth, Momentum, and Stability, <a href="https://stocknews.com/stock/LFVN/">click here</a>.
Hudson Global, Inc. (<a href="https://stocknews.com/stock/HSON/">HSON</a>)
With a market cap of $46.97 million, HSON provides talent solutions for mid-to-large-cap multinational companies and government agencies under the Hudson RPO brand in the Americas, the Asia Pacific, and Europe. It offers recruitment process outsourcing (RPO) services and RPO contracting services.
On March 12, HSON announced the acquisition of Executive Solutions, a talent solutions company based in Dubai. This acquisition provides the company access to the large and rapidly growing United Arab Emirates (UAE) market.
Jeff Eberwein, CEO of Hudson Global, said, "The acquisition of Executive Solutions further expands our global footprint and client base and brings significant value to our shareholders. We are excited to expand our footprint in the Middle East market and participate in the significant growth opportunities this region has to offer as we continue to execute our strategy of global expansion through organic and inorganic growth."
In terms of forward EV/Sales, HSON is trading at 0.16x, 90.8% lower than the industry average of 1.74x. Likewise, the stock's forward Price/Sales and Price/Cash Flow multiples of 0.28 and 8.33 are 80.1% and 35.6% below their respective industry averages of 1.41 and 12.93.
Moreover, the stock's trailing-12-month asset turnover ratio of 2.44x is 212.9% higher than the 0.78x industry average.
HSON's revenue for the first quarter that ended March 31, 2024, came in at $33.89 million. Its total operating expenses decreased 14.2% year-over-year to $36.93 million. Additionally, the company used $1.80 million in cash flow from operations during the first quarter, compared to an outflow of $5 million in the same period last year. As of March 31, 2024, its cash and cash equivalents stood at $20.41 million.
Analysts expect HSON's EPS for the third quarter ending September 2024, to increase 16.7% year-over-year to $0.28. Its revenue for the current quarter is expected to grow 15.2% year-over-year to $45.38 million.
Over the past month, the stock has gained 3.2% to close the last trading session at $15.74.
It's no surprise that HSON has an overall rating of A, which translates to a Strong Buy in our POWR Ratings system.
It has an A grade for Value and Sentiment and a B for Quality. It is ranked first in the A-rated <a href="https://stocknews.com/category/outsourcing-staffing-services/">Outsourcing – Staffing Services</a> industry. <a href="https://stocknews.com/stock/HSON/">Click here</a> to see the other HSON ratings for Growth, Momentum, and Stability.
SigmaTron International, Inc. (<a href="https://stocknews.com/stock/SGMA/">SGMA</a>)
SGMA provides a range of electronic manufacturing services (EMS), specializing in printed circuit board assemblies, electro-mechanical subassemblies, and fully assembled electronic products. Additionally, the company offers comprehensive support services, including assembly and testing, material sourcing, engineering support, design, warehousing, distribution, compliance reporting, and regulatory approval assistance. It has a market cap of $34.37 million.
In terms of trailing-12-month non-GAAP P/E, SGMA is trading at 5.64x, which is 81.1% lower than the industry average of 29.81x. The stock's trailing-12-month EV/EBITDA of 5.37x is 71.1% lower than the industry average of 18.57x. Also, its trailing-12-month EV/Sales multiple of 0.32 compares to the industry average of 3.13.
SGMA's trailing-12-month ROCE and ROTC of 8.96% and 6.22% are 109.8% and 130.2% higher than the respective industry averages of 4.27% and 2.70%. Likewise, its 1.54x trailing-12-month asset turnover ratio is 147.5% higher than the 0.62x industry average.
SGMA's net sales for the third quarter, which ended on January 31, 2024, increased 3.4% year-over-year to $95.92 million. Its net income amounted to $599.01 thousand and $0.10 per share compared to the prior-year quarter's loss of $23.08 million and $3.81 per share. The company's net cash inflow from operating activities stood at $16.84 million, compared to an outflow of $27.65 million in the same period last year.
Shares of SGMA have gained 74.5% over the past year and 87.9% year-to-date to close the last trading session at $5.66.
SGMA's POWR Ratings reflect its solid prospects. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Growth and Value and a B for Momentum, Sentiment, and Quality. SGMA is ranked first out of 38 stocks in the B-rated <a href="https://stocknews.com/category/technology-hardware/">Technology - Hardware</a> industry. In addition to the POWR Ratings highlighted above, one can access SGMA's Stability rating <a href="https://stocknews.com/stock/SGMA/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>
 

<hr />
LFVN shares were trading at $6.32 per share on Tuesday afternoon, up $0.03 (+0.48%). Year-to-date, LFVN has gained 6.42%, versus a 15.97% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/lfvn-hson-sgma-3-undervalued-small-cap-stocks-to-buy-before-they-take-off/>3 Undervalued Small-Cap Stocks to Buy Before They Take Off</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Undervalued Small-Cap Stocks to Buy Before They Take Off

Micro-cap stocks carry high risk but can potentially deliver high returns. Given this backdrop, it could be wise to buy under-the-radar micro-cap stocks LifeVantage (LFVN), Pro-Dex (PDEX), and Lee Enterprises (LEE), which have high growth potential. Keep reading… Micro-cap stocks have the potential for rapid growth, particularly if they belong to high-growth industries or possess disruptive business models. This can lead to significant gains for investors who can identify and invest in promising micro-cap stocks.
Therefore, investors could consider buying fundamentally sound micro-cap stocks, LifeVantage Corporation (<a href="https://stocknews.com/stock/LFVN/">LFVN</a>), Pro-Dex, Inc. (<a href="https://stocknews.com/stock/PDEX/">PDEX</a>), and Lee Enterprises, Incorporated (<a href="https://stocknews.com/stock/LEE/">LEE</a>).
<a href="https://www.investopedia.com/terms/m/microcapstock.asp">Micro-cap stocks</a> have a market capitalization that lies approximately between $50 million and $300 million. These stocks emphasize long-term growth and operate with high efficiency, concentrating on expanding their businesses. Therefore, when chosen wisely, micro-caps can be highly beneficial for investors.
Moreover, micro-cap stocks can offer substantial returns, but high-quality ones often go unnoticed due to the limited media coverage they receive compared to large companies. Despite this, they have a history of outperformance. A <a href="https://www.boston-partners.com/uploads/2021/05/35500a7549a9e095691c5f66819b4d87/wpg-microcap-vs-pe-white-paper.pdf">Boston Partners report</a> shows that from early 1995 to June 2020, the CRSP Equal Weighted Microcap Index grew by 740%, surpassing the S&amp;P 500's 255% returns.
Considering these encouraging trends, let's take a look at the fundamentals of the three best micro-cap stocks.
LifeVantage Corporation (<a href="https://stocknews.com/stock/LFVN/">LFVN</a>)
LFVN engages in identifying, researching, developing, formulating, selling, and distributing nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. It has a market cap of $80.20 million.
On May 2, 2024, the company paid its shareholders a quarterly dividend of $0.04 per share. The company pays an annual dividend of $0.16, which translates to a 2.47% yield with a four-year average yield of 2.51%.
In terms of forward non-GAAP P/E, LFVN is trading at 9.95x, 42.4% lower than the industry average of 17.29x. Likewise, the stock's forward EV/Sales and <a href="https://www.investopedia.com/terms/p/price-to-salesratio.asp">Price/Sales</a> multiples of 0.39 and 0.41 are 78% and 68.9% lower than their respective industry averages of 1.76 and 1.31.
In the third quarter, which ended March 31, 2023, LFVN reported revenue and gross profit of $48.25 million and $38.07 million, respectively. The company's non-GAAP net income and adjusted EPS amounted to $2.78 million and $0.21, up 169.9% and 162.5% year-over-year, respectively.
For the fiscal first quarter ending September 2024, LFVN's revenue is expected to amount to $49.63 million, while its EPS is forecasted to settle at $0.16. Further, its EPS and revenue are expected to rise 7.7% and 1.8% year-over-year to $0.70 and $205.84 million, respectively, in the fiscal year ending June 2025. Moreover, it topped the consensus EPS estimates in three of the trailing four quarters.
Over the past year, the stock has gained 44.5% to close the last trading session at $6.47.
LFVN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
LFVN has an A grade for Value, Sentiment, and Quality. The stock is ranked #2 out of 10 stocks within the A-rated <a href="https://stocknews.com/category/medical-consumer-goods/">Medical - Consumer Goods</a> industry.
To see the other ratings of LFVN for Growth, Momentum, and Stability, <a href="https://stocknews.com/stock/LFVN/">click here</a>.
Pro-Dex, Inc. (<a href="https://stocknews.com/stock/PDEX/">PDEX</a>)
By market cap, PDEX is valued at $65.13 million. It designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide.
In terms of forward EV/EBITDA, PDEX is trading at 8.35x, 39.1% lower than the industry average of 13.70x. Likewise, the stock's forward EV/Sales and Price/Sales multiples of 1.40 and 1.32 are 61.4% and 65.8% lower than their respective industry averages of 3.63 and 3.86.
In the third quarter that ended March 31, 2024, PDEX's net sales increased 3.9% year-over-year to $14.29 million, and its gross profit grew 5% year-over-year to $4 million. The company's net income and net income per share amounted to $ 655 thousand and $0.19, respectively.
Analysts expect PDEX's revenue for the quarter ending December 2024 to increase marginally year-over-year to $12.70 million. Its EPS for the same period is expected to increase 128.6% year-over-year to $0.32. Moreover, it topped the consensus revenue estimates in three of the trailing four quarters.
Shares of PDEX have surged 12.3% over the past nine months to close the last trading session at $19.05.
PDEX's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
PDEX has a B grade for Quality, Stability, Sentiment, and Value. It is ranked #3 out of 77 stocks in the A-rated <a href="https://stocknews.com/category/industrial-machinery/">Industrial - Machinery</a> industry.
In addition to the POWR Ratings highlighted above, you can check PDEX's ratings for Momentum and Growth <a href="https://stocknews.com/stock/PDEX/">here</a>.
Lee Enterprises, Incorporated (<a href="https://stocknews.com/stock/LEE/">LEE</a>)
Valued at $62.48 million by market cap, LEE provides local news and information, and advertising services in the United States. The company offers digital subscription platforms; daily, weekly, and monthly newspapers and niche publications; and web hosting and content management services.
LEE's forward EV/Sales and Price/Sales multiples of 0.86 and 0.10 are 55.4% and 92.1% lower than their respective industry averages of 1.93 and 1.25.
LEE's total operating revenue was reported at $146.55 million for the third quarter that ended March 24, 2024, and digital subscription revenue grew 44.8% year-over-year to $20.26 million. The company's adjusted EBITDA increased 5.2% from the year-ago value to $15.06 million.
Analysts expect LEE's EPS to grow 172% year-over-year to $0.68 for the quarter ended June 2024. Its revenue is expected to be $165.48 million. Also, the company has topped the consensus revenue estimates in three of the four trailing quarters, which is remarkable.
LEE's stock has gained 29.2% year-to-date to close the last trading session at $10.17.
LEE's POWR Ratings reflect its solid prospects. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. 
LEE has a B grade for Growth, Sentiment, and Value. Within the A-rated <a href="https://stocknews.com/category/entertainment-publishing/">Entertainment - Publishing</a> industry, it is ranked first out of eight stocks.
To see LEE's additional ratings for Momentum, Stability, and Quality, <a href="https://stocknews.com/stock/LEE/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
LFVN shares were trading at $6.58 per share on Tuesday afternoon, up $0.11 (+1.70%). Year-to-date, LFVN has gained 10.80%, versus a 17.43% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/lfvn-pdex-lee-3-under-the-radar-micro-cap-stocks-to-buy/>3 Under-the-Radar Micro-Cap Stocks to Buy</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Under-the-Radar Micro-Cap Stocks to Buy

LifeVantage (LFVN) has issued an update. Erin Brockovich resigned from the Board of Directors of LifeVantage Corporation, effective August 26, 2024...

LifeVantage Announces Board Reshuffle and New Director Appointment

LifeVantage Q4 2024 Earnings Preview

Here's the major earnings after the close today

LifeVantage Non-GAAP EPS of $0.14 misses by $0.07, revenue of $48.93M misses by $2.02M

LifeVantage declares $0.04 dividend

LifeVantage Corporation (LFVN) Q4 2024 Earnings Call Transcript

AFRM

APLD

CRWD

FIVE

HSON

IREN

MESO

NOAH

NTAP

NTNX

NVDA

OKTA

PDEX

PSTG

SGMA

VEEV

VSCO

Press Releases

LifeVantage To Host "LifeVantage Open House" Virtual Calls on July 23 and 24

LifeVantage Optimizes Rewards Circle with New Benefits for Both Consultants and Customers

Health Care

LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2024 Results on August 28, 2024

LifeVantage Concludes Rise Retreat in Park City with Exclusive Preview of New Innovative Weight Management Solution

LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service

Dividends

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2024

LifeVantage Declares Quarterly Dividend

Restaurants

LifeVantage Welcomes Back AXIO® Lemonade—Now As a Permanent Flavor

LifeVantage to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LifeVantage Announces Positive In Vitro Results for New GLP-1 System Showing Synergistic Gene Activation for Enhanced Weight Management* †

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Lifevantage

Lifevantage (LFVN) Forecast

Lifevantage (NASDAQ:LFVN) Stock, Quote.Headers.trade-ideas